Stock CGEN COMPUGEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Compugen Ltd. TEL AVIV STOCK EXCHANGE

Equities

CGEN

IL0010852080

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 10:24:18 2024-05-07 am EDT 		5-day change 1st Jan Change
793.5 ILa -1.37% Intraday chart for Compugen Ltd. +7.62% +15.33%
Mar. 08 Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating MT
Mar. 05 Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
PR
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
AQ
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
PU
Compugen to Participate in Two Upcoming Investor Conferences
PR
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PU
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
PR
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
AQ
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
PU
Compugen: Q4 Earnings Snapshot
AQ
Compugen : Form 6-K- Fourth quarter and full year 2023 results
PU
Compugen Reports Fourth Quarter and Full Year 2023 Results
PR
Compugen to Present at the Leerink Partners Global Biopharma Conference 2024
PR
Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024
PR
Compugen names new chief medical officer
AQ
Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer
PR
Compugen : 6K-License Agreement with Gilead and entitlement to receive a milestone payment of $10 million from AstraZeneca
PU
Compugen: Q3 Earnings Snapshot
AQ
Compugen Reports Third Quarter 2023 Results
PR
Compugen's COM701 Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
AQ
Compugen to Present New Clinical and Pre-Clinical Data in Multiple Presentations at SITC 2023
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEN Stock
  4. CGEN Stock
  5. News Compugen Ltd.
  6. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW